MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 3,000 shares of the firm's stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $3.82, for a total value of $11,460.00. Following the completion of the transaction, the director now owns 141,950 shares in the company, valued at approximately $542,249. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
John Joseph Johnston also recently made the following trade(s):
- On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.28, for a total value of $12,840.00.
- On Friday, July 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.75, for a total value of $14,250.00.
MaxCyte Stock Performance
Shares of MaxCyte stock opened at $3.89 on Tuesday. MaxCyte, Inc. has a one year low of $2.45 and a one year high of $5.55. The company has a market cap of $407.77 million, a price-to-earnings ratio of -11.11 and a beta of 1.40. The business's 50 day moving average price is $4.19 and its 200 day moving average price is $4.26.
Protect Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings | Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The company had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the previous year, the business earned ($0.10) earnings per share. On average, analysts predict that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.
Institutional Investors Weigh In On MaxCyte
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD raised its position in MaxCyte by 20.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company's stock valued at $106,000 after purchasing an additional 4,320 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in MaxCyte by 22.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company's stock valued at $128,000 after purchasing an additional 5,927 shares during the period. PNC Financial Services Group Inc. acquired a new stake in shares of MaxCyte in the fourth quarter valued at $29,000. Russell Investments Group Ltd. acquired a new stake in shares of MaxCyte in the first quarter valued at $28,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 19,884 shares of the company's stock valued at $83,000 after buying an additional 7,898 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.
MaxCyte Company Profile
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
